Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

vasogen

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
54) TREATMENT OF AUTOIMMUNE DISEASES 4,632,980 12/1986 Zee et al. ................................ 530/380 4,831,268 5/1989 Fisch… Expand
Review
2009
Review
2009
The increasing prevalence of heart failure poses enormous challenges for health care systems worldwide. Despite effective medical… Expand
Highly Cited
2008
Highly Cited
2008
Background—Atherothrombosis is the underlying cause of cardiovascular, cerebrovascular, and peripheral arterial disease and is… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
2008
2008
Administration of VP025 (Vasogen Inc.), a novel drug formulation based on phospholipid nanoparticles incorporating… Expand
2008
2008
Yvonne Nolan, Frank O. Maher||, Darren S. Martin, Rachael M. Clarke, Miriam T. Brady, Anthony E Bolton, Kingston H. G. Mills, and… Expand
2005
2005
We have reported that Vasogen’s immune modulation therapy (IMT), a procedure involving intramuscular administration of autologous… Expand
  • figure 1
2003
2003
AIM Vasogen's immune modulation therapy (IMT)* involves the ex vivo exposure of a sample of autologous blood to 3 oxidative… Expand
2002
2002
Systemic injection of lipopolysaccharide (LPS) blocks the expression of long-term potentiation in the hippocampus of the rat… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
2002
2002
OBJECTIVES this study examined the effect of immune modulation therapy (IMT) on claudication distances. MATERIALS AND METHODS a… Expand
  • table 1
  • table 3
  • table 4
  • table 2
Review
2001
Review
2001
  • F. Visioli
  • Current opinion in investigational drugs
  • 2001
  • Corpus ID: 19207735
Vasogen is developing VasoCare, an immune modulation therapy, as a potential treatment for peripheral vascular disease (PVD) and… Expand